You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors
Free

 

Online download statistics by month:

Online download statistics by month: November 2021 to August 2024

AbstractFullPdf
Nov 202128809
Dec 202192013
Jan 20226609
Feb 202286011
Mar 2022212014
Apr 2022104017
May 202264018
Jun 202266015
Jul 20223607
Aug 20223404
Sep 202262012
Oct 202250013
Nov 20222006
Dec 20223402
Jan 20232404
Feb 20234609
Mar 20233601
Apr 20232402
May 20231603
Jun 202342010
Jul 202350012
Aug 20233404
Sep 20232208
Oct 20232605
Nov 20233803
Dec 20233602
Jan 20244203
Feb 20244206
Mar 20242002
Apr 20242007
May 20242203
Jun 20243906
Jul 20241405
Aug 20241405
Total18210250